The adeno-associated viral vector market is anticipated to grow at a CAGR of more than 10% by 2035, claims Roots Analysis
Given their low immunogenicity, diversified targets and ability to offer higher biosafety, the adeno-associated viral vectors are actively being evaluated for the development of various therapies for the treatment of chronic diseases and infections.
For additional details, please visit https://www.rootsanalysis.com/....reports/adeno-associ or email [email protected]
